Zobrazeno 1 - 10
of 149
pro vyhledávání: '"Valesca P, Retèl"'
Autor:
Lucas Frederik van Schaik, Ellen Gurumay Engelhardt, Wim Herbert van Harten, Valesca Pavlawna Retèl
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Background Comprehensive genomic profiling (CGP) can identify targets beyond standard of care, potentially revolutionizing personalized cancer management. However, conducting well designed studies in this rapidly evolving field is complex an
Externí odkaz:
https://doaj.org/article/dfa775076b254ef5919331a8af7dd92e
Autor:
Astrid Kramer, Carmen Rubio‐Alarcón, Daan van denBroek, Daan C. L. Vessies, Iris van't Erve, Gerrit A. Meijer, Geraldine R. Vink, Ed Schuuring, Remond J. A. Fijneman, Veerle M. H. Coupé, Valesca P. Retèl
Publikováno v:
Molecular Oncology, Vol 18, Iss 11, Pp 2730-2742 (2024)
Circulating tumor DNA (ctDNA) detection has multiple promising applications in oncology, but the road toward implementation in clinical practice is unclear. We aimed to support the implementation process by exploring potential future pathways of ctDN
Externí odkaz:
https://doaj.org/article/4e90fa3c429847ecbf02abb2a149a0e3
Autor:
Joost G.E. Verbeek, Leyla Azarang, Luis E. Pilli, Vincent M.T. de Jong, Agnes Jager, Sabine C. Linn, Valesca P. Retèl, Wim H. van Harten
Publikováno v:
Acta Oncologica, Vol 63, Iss 1 (2024)
Background and purpose: High-dose chemotherapy with autologous stem cell rescue (HDCT) is currently under investigation as a potential therapy for patients with stage III HER2-negative breast cancer with homologous recombination deficiency (HRD). In
Externí odkaz:
https://doaj.org/article/20428d92475a4fe8be71426416fab27c
Autor:
Astrid Kramer, Marjolein J. E. Greuter, Suzanna J. Schraa, Geraldine R. Vink, Jillian Phallen, Victor E. Velculescu, Gerrit A. Meijer, Daan van den Broek, Miriam Koopman, Jeanine M. L. Roodhart, Remond J. A. Fijneman, Valesca P. Retèl, Veerle M. H. Coupé
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 16 (2024)
Background: Current patient selection for adjuvant chemotherapy (ACT) after curative surgery for stage II colon cancer (CC) is suboptimal, causing overtreatment of high-risk patients and undertreatment of low-risk patients. Postoperative circulating
Externí odkaz:
https://doaj.org/article/df477bb60b4f45289ac535ad731952c5
Autor:
Eline M J Lammers, Josée M Zijlstra, Valesca P Retèl, Berthe M P Aleman, Flora E van Leeuwen, Annelies Nijdam
Publikováno v:
JMIR Research Protocols, Vol 13, p e55601 (2024)
BackgroundHodgkin lymphoma (HL) occurs at young ages, with the highest incidence between 20 and 40 years. While cure rates have improved to 80%-90% over the past decades, survivors of HL are at substantial risk of late treatment–related complicatio
Externí odkaz:
https://doaj.org/article/96733ba3b3c14f89b8567a50ad39b2a8
Autor:
John Haanen, Marco Donia, Inge Marie Svane, Bastiaan Nuijen, Cynthia Nijenhuis, Valesca P Retèl, Tine Monberg, Renske M T ten Ham, Maartje W Rohaan, Inge Jedema, Rob Kessels, Wim Stegeman, Walter Scheepmaker, Melanie Lindenberg, Wim van Harten
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 3 (2024)
Introduction In a multicenter, open-label randomized phase 3 clinical trial conducted in the Netherlands and Denmark, treatment with ex vivo-expanded tumor-infiltrating lymphocytes (TIL-NKI/CCIT) from autologous melanoma tumor compared with ipilimuma
Externí odkaz:
https://doaj.org/article/861ff4b06089417c8f45e19942083ea2
Autor:
Ruby M. van Stein, Florine J. Hendriks, Valesca P. Retèl, Cor D. de Kroon, Christianne A.R. Lok, Gabe S. Sonke, Kelly M. de Ligt, Willemien J. van Driel
Publikováno v:
Gynecologic Oncology Reports, Vol 50, Iss , Pp 101293- (2023)
Purpose: Measuring health-related quality of life (HRQoL) in ovarian cancer patients is critical to understand the impact of disease and treatment. Preference-based HRQoL measures, called health state utilities, are used specifically in health econom
Externí odkaz:
https://doaj.org/article/b5cf6e67f45f4faf825b7fef5a01c0df
Autor:
Joost G. E. Verbeek, Vincent M. T. de Jong, Hanna M. Wijnja, Agnes Jager, Sabine C. Linn, Valesca P. Retèl, Wim H. van Harten
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-11 (2023)
Abstract Background High-dose chemotherapy with autologous stem cell rescue (HDCT) is a promising treatment for patients with stage III, HER2-negative, homologous recombination deficient (HRD) breast cancer. Clinical effectiveness and cost-effectiven
Externí odkaz:
https://doaj.org/article/5fd17baec0f84cdea280548a6e6950e0
Autor:
Melanie A. Lindenberg, Valesca P. Retèl, Henk G. van der Poel, Ferdau Bandstra, Carl Wijburg, Wim H. van Harten
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-11 (2022)
Abstract Robot-Assisted Radical Prostatectomy (RARP) is one of the standard treatment options for prostate cancer. However, controversy still exists on its added value. Based on a recent large-sample retrospective cluster study from the Netherlands s
Externí odkaz:
https://doaj.org/article/5510282af9dc4f81ad58929fef0e31d2
Autor:
Marinda Meertens, M. Benthe Muntinghe-Wagenaar, Barend J. Sikkema, Marta Lopez-Yurda, Valesca P. Retèl, Marthe S. Paats, Rob Ter Heine, Ed Schuuring, Wim Timens, Daan J. Touw, Job F. M. van Boven, Adrianus. J. de Langen, Sayed M. S. Hashemi, Lizza E. L. Hendriks, Sander Croes, Michel M. van den Heuvel, Anne-Marie C. Dingemans, Ron H. J. Mathijssen, Egbert F. Smit, Alwin D. R. Huitema, Neeltje Steeghs, Anthonie J. van der Wekken
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundAlectinib is first-line therapy in patients with stage IV non-small cell lung carcinoma (NSCLC) and an anaplastic lymphoma kinase (ALK) fusion. A shorter median progression-free survival (mPFS) was observed when alectinib minimum plasma con
Externí odkaz:
https://doaj.org/article/4457ff0cdd7b4bd9aa0922759784c7a7